[{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Phosphorylated hexaacylated disaccharide","moa":"TLR4","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Revelation Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Revelation Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Revelation Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"REVTx\u201199","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Revelation Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intranasal spray","sponsorNew":"Revelation Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Revelation Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Global Health Investment Advisors","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2021","type":"Series A Financing","leadProduct":"Phosphorylated hexaacylated disaccharide","moa":"TLR4","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Revelation Biosciences","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"intranasal spray","sponsorNew":"Revelation Biosciences \/ Global Health Investment Advisors","highestDevelopmentStatusID":"6","companyTruncated":"Revelation Biosciences \/ Global Health Investment Advisors"},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"National Securities Corporation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2021","type":"Series A Financing","leadProduct":"Phosphorylated hexaacylated disaccharide","moa":"TLR4","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Revelation Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"intranasal spray","sponsorNew":"Revelation Biosciences \/ National Securities Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Revelation Biosciences \/ National Securities Corporation"},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Petra Acquisition","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2021","type":"Merger","leadProduct":"Phosphorylated Hexaacyl Disaccharide","moa":"Interferon-Induced Protein-10","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Revelation Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Drop Solution","sponsorNew":"Revelation Biosciences \/ Petra Acquisition","highestDevelopmentStatusID":"6","companyTruncated":"Revelation Biosciences \/ Petra Acquisition"},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Phosphorylated HexaAcyl Disaccharide","moa":"TLR4","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Revelation Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intranasal drop","sponsorNew":"Revelation Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Revelation Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Phosphorylated Hexaacyl Disaccharide","moa":"Interferon-Induced Protein-10","graph1":"Immunology","graph2":"Phase I","graph3":"Revelation Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intranasal Drop","sponsorNew":"Revelation Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Revelation Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Destum Partners","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2021","type":"Partnership","leadProduct":"Phosphorylated HexaAcyl Disaccharide","moa":"TLR4","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Revelation Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intranasal Drop","sponsorNew":"Revelation Biosciences \/ Destum Partners","highestDevelopmentStatusID":"6","companyTruncated":"Revelation Biosciences \/ Destum Partners"},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Phosphorylated Hexa-acyl Disaccharide","moa":"TLR4","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Revelation Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Revelation Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Revelation Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Phosphorylated Hexaacyl Disaccharide","moa":"TLR4","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Revelation Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Revelation Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Revelation Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Phosphorylated Hexaacyl Disaccharide","moa":"TLR4","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Revelation Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Revelation Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Revelation Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"REVTx-99b","moa":"CCR3","graph1":"Immunology","graph2":"Phase I","graph3":"Revelation Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Revelation Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Revelation Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Phosphorylated Hexaacyl Disaccharide","moa":"TLR4","graph1":"Immunology","graph2":"Phase I","graph3":"Revelation Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oil\/Drops","sponsorNew":"Revelation Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Revelation Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"REVTx-99b","moa":"CCR3","graph1":"Immunology","graph2":"Phase I","graph3":"Revelation Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Revelation Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Revelation Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2022","type":"Public Offering","leadProduct":"REVTx-99b","moa":"CCR3","graph1":"Immunology","graph2":"Phase I","graph3":"Revelation Biosciences","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"Spray","sponsorNew":"Revelation Biosciences \/ Roth Capital Partners","highestDevelopmentStatusID":"6","companyTruncated":"Revelation Biosciences \/ Roth Capital Partners"},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2022","type":"Public Offering","leadProduct":"REVTx-99b","moa":"CCR3","graph1":"Immunology","graph2":"Phase I","graph3":"Revelation Biosciences","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"Spray","sponsorNew":"Revelation Biosciences \/ Roth Capital Partners","highestDevelopmentStatusID":"6","companyTruncated":"Revelation Biosciences \/ Roth Capital Partners"},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"REVTx-99b","moa":"CCR3","graph1":"Immunology","graph2":"Phase I","graph3":"Revelation Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Revelation Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Revelation Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"REVTx-300","moa":"TLR4","graph1":"Nephrology","graph2":"Preclinical","graph3":"Revelation Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"Revelation Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Revelation Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"REVTx-300","moa":"","graph1":"Nephrology","graph2":"Preclinical","graph3":"Revelation Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"Revelation Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Revelation Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"REVTx-100","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Revelation Biosciences","amount2":0.02,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"","sponsorNew":"Revelation Biosciences \/ Roth Capital Partners","highestDevelopmentStatusID":"4","companyTruncated":"Revelation Biosciences \/ Roth Capital Partners"},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"REVTx-300","moa":"","graph1":"Nephrology","graph2":"Preclinical","graph3":"Revelation Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"Revelation Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Revelation Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"REVTx-100","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Revelation Biosciences","amount2":0.02,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"","sponsorNew":"Revelation Biosciences \/ Roth Capital Partners","highestDevelopmentStatusID":"4","companyTruncated":"Revelation Biosciences \/ Roth Capital Partners"},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"REVTx-100","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Revelation Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Revelation Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Revelation Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2024","type":"Public Offering","leadProduct":"Phosphorylated Hexaacyl Disaccharide","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Revelation Biosciences","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"","sponsorNew":"Revelation Biosciences \/ Roth Capital Partners","highestDevelopmentStatusID":"6","companyTruncated":"Revelation Biosciences \/ Roth Capital Partners"},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2024","type":"Public Offering","leadProduct":"Phosphorylated Hexaacyl Disaccharide","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Revelation Biosciences","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"","sponsorNew":"Revelation Biosciences \/ Roth Capital Partners","highestDevelopmentStatusID":"6","companyTruncated":"Revelation Biosciences \/ Roth Capital Partners"},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Phosphorylated Hexaacyl Disaccharide","moa":"","graph1":"Nephrology","graph2":"Phase I","graph3":"Revelation Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"Revelation Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Revelation Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"RVL-HV02","moa":"","graph1":"Nephrology","graph2":"Phase I","graph3":"Revelation Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"Revelation Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Revelation Biosciences \/ Not Applicable"}]
Find Clinical Drug Pipeline Developments & Deals by Revelation Biosciences
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
